[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551164":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":31,"locations":41,"responsibleParty":69,"collaborators":11,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":11,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"QL0911","EXPERIMENTAL",null,[13],"Drug: QL0911",{"label":15,"type":10,"description":11,"interventionNames":16},"QL0911 plus Placebo",[17],"Drug: QL0911 plus Placebo",{"label":19,"type":20,"description":11,"interventionNames":21},"Placebo","PLACEBO_COMPARATOR",[22],"Drug: Placebo",[24,27,29],{"type":25,"name":9,"description":9,"armGroupLabels":26,"otherNames":11},"DRUG",[9],{"type":25,"name":15,"description":15,"armGroupLabels":28,"otherNames":11},[15],{"type":25,"name":19,"description":19,"armGroupLabels":30,"otherNames":11},[19],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Jun Ma","CONTACT","0451-84883471","majun0322@126.com",{"name":38,"role":34,"phone":39,"phoneExt":11,"email":40},"Shukui Qin","025-84453932","qinsk81@163.com",[42,58],{"facility":43,"status":44,"city":45,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Harbin First Hospital","RECRUITING","Harbin","China","CN",{"type":49,"coordinates":50},"Point",[51,52],126.65,45.75,{"lat":52,"lon":51},[55],{"name":56,"role":34,"phone":57,"phoneExt":11,"email":36},"Chief Physician","+86-0451-84883471",{"facility":59,"status":44,"city":60,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Nanjing Tianyinshan Hospital","Nanjing",{"type":49,"coordinates":62},[63,64],118.77778,32.06167,{"lat":64,"lon":63},[67],{"name":56,"role":34,"phone":68,"phoneExt":11,"email":40},"+86-025-84453932",{"type":70,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100551164","phase-2-ql0911-for-the-treatment-of-cancer-treatment-induced-thrombocytopenia-100551164",false,"NCT06456528","QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia","Phase 2\u002F3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.","Inclusion Criteria:\n\n* Men and women, 18-75 years of age;\n* Histopathological or cytological examination confirmed cancer , chemotherapy cycle of 21 days;\n* Participant experienced thrombocytopenia and chemotherapy delay;\n* ECOG performance status 0-1;\n* The estimated survival time at screening is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles.\n\nExclusion Criteria:\n\n* Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia;\n* Participant has serious bleeding symptoms;\n* History of allergy to the study drug;\n* Patients with hepatitis C antibody positive and detection of HCV-RNA exceeding the upper limit, patients with hepatitis B surface antigen positive and detection of HBV-DNA exceeding the upper limit, patients with severe cirrhosis, HIV antibody positive and syphilis antibody positive;\n* Pregnant or lactating women;\n* Participant has received any experimental therapy within 28 days prior to screening\n* Other conditions that may affect participant's safety or trial evaluations per investigator's discretion","ALL","18 Years","75 Years",{"count":82,"type":83},235,"ESTIMATED","INTERVENTIONAL",[86,87],"PHASE2","PHASE3","To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.",[90],"Cancer Treatment-Induced Thrombocytopenia","2026-01-08",{"date":93,"type":94},"2026-01-12","ACTUAL",{"date":96,"type":94},"2024-10-22",{"date":98,"type":83},"2026-12",{"name":5,"class":6},2]